Haystack Oncology has developed a highly sensitive minimal-residual disease (MRD) testing technology, based on circulating tumor DNA (ctDNA), to aid in the early detection of residual or recurring cancer and better inform therapy decisions.
Acquired back in April, the acquisition will leverage Quest’s expertise and scale in oncology, genomics and pathology. Quest expects to incorporate this MRD technology into the development of new blood-based clinical lab services for solid tumor cancers available beginning in 2024.
EQS-News: Adrenomed AG / Key word(s): Miscellaneous AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock 10.04.2024 / 14:00 CET/CEST The
Springtime is associated with renewal, as nature emerges from its winter slumber, accompanied by the return of color, a chorus of birdsong, and the delicate
Advantus Health Partners forms a new 10-year, $2.9B strategic partnership with Medline to establish agility and scale, supply chain resiliency and enhanced clinical integration with
Quest Diagnostics Completes Acquisition of Haystack Oncology
by Healthcare M&A Leave a Comment
What You Should Know:
AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock – Biotech Investments
EQS-News: Adrenomed AG / Key word(s): Miscellaneous AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock 10.04.2024 / 14:00 CET/CEST The
Here’s What Diagnostic Testing Can Do for Your Allergy Patients
Springtime is associated with renewal, as nature emerges from its winter slumber, accompanied by the return of color, a chorus of birdsong, and the delicate
Roundups: 21 Recent Strategic Digital Health Partnerships
Advantus Health Partners forms a new 10-year, $2.9B strategic partnership with Medline to establish agility and scale, supply chain resiliency and enhanced clinical integration with